Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $420

Truist Securities analyst Gregory Renza has maintained a Buy rating on BeOne Medicines (NASDAQ: ONC) and raised the price target from $418 to $420. This adjustment reflects a positive outlook for the company's performance.